The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Pembrolizumab monotherapy for older/ABVD-ineligible patients with Hodgkin lymphoma
Currently, there is no standard of care for older patients who develop classical Hodgkin lymphoma (cHL), and conventional chemotherapy is associated with several toxicities. In this video, Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, shares some insights into a study evaluating the safety and efficacy of pembrolizumab monotherapy in patients with cHL ineligible for frontline ABVD. Prof. Dickinson discusses the inclusion criteria for this trial, and further summarizes the results, including the progression-free and overall survival (PFS; OS) rates observed. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Roche, AbbVie, GenMab, Novartis, Kite, Gilead, Bristol Myers Squibb
Research funding: Roche, Novartis, Gilead, Takeda
